Description]: the product can be used with Bioda immune detector to quantitatively detect troponin I in human whole blood, serum and plasma, and it can provide the reference for clinical diagnosis of myocardial infarction.

● Detection of cTnI in patients with chest pain and local bleeding can help early diagnosis of myocardial infarction
● To reduce the diagnosis risk of AMI patients in development, cTnI can be used to provide a good diagnosis method

[Detailed information]: Bioda cTnI produced by our company is an in-vitro diagnostic reagent used to detect cTnI in human whole blood, serum and plasma.

In intact myocardial cell membrane, cTnI cannot enter the blood circulation through the cell membrane, so there is no or very low cTnI in the blood of healthy people. In patients with acute myocardial infarction, the cTnI released to the circulatory system will exceed the normal upper limit about 4-6h after the onset of symptom; in 12-24h after such onset, the cTnI concentration will reach the peak value, and then maintain a high level for 6-10 days. Since cTnI has high myocardial specificity and sensitivity, it is a relatively good definitive myocardial marker for early AMI diagnosis, prognosis evaluation and early unstable angina pectoris diagnosis.   
 
With the detection of cTnI, the results are more sensitive and accurate, which greatly improves the timeliness and accuracy of clinical detection.  

[Reaction time]: 12min
[Detection range]: cTnI: 0.05-50ng/ml
[Clinical Significance]: diagnosis of myocardial damage and acute myocardial infarction (AMI)
[Application departments]: Outpatient Department, Emergency Department, Cardiology Department, Thoracic Surgery Department, Ambulance, Ward, ICU, Geriatrics Department

[Interpretation Method]: